CyDex Pharmaceuticals Overview
- Founded
-
1993

- Status
-
Acquired/Merged
- Employees
-
32

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$35.5M
CyDex Pharmaceuticals General Information
Description
Provider of drug delivery technology. The company's drug delivery technology uses four Captisol-enabled products commercialized by Pfizer and Bristol-Myers Squibb (BMS) to address asthma, depression, allergy, cancer and arrhythmia disease states.
Contact Information
Website
www.captisol.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Parent Company
Primary Office
- 10513 West 84th Terrace
- Lenexa, KS 66214
- United States
+1 (913) 000-0000
CyDex Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Merger/Acquisition | 26-Jan-2011 | $35.5M | 0000 | 000.00 | Completed | Clinical Trials - Phase 2 |
4. Later Stage VC | 24-Mar-2010 | 000.00 | 0000 | Completed | Generating Revenue | |
3. IPO | 28-Oct-2008 | 0000 | Cancelled | Clinical Trials - Phase 2 | ||
2. Early Stage VC (Series B) | 17-Aug-2004 | $17M | $29M | 000.00 | Completed | Clinical Trials - Phase 2 |
1. Early Stage VC (Series A) | 11-Oct-2000 | $12M | $12M | 000.00 | Completed | Clinical Trials - Phase 2 |
CyDex Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series A1 | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 0.000 |
Series A | 16,464,622 | $0.010000 | 7% | $0.73 | $0.73 | 1x | $0.73 | 15.99% |
CyDex Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of drug delivery technology. The company's drug delivery technology uses four Captisol-enabled products commerc
Drug Delivery
Lenexa, KS
32
As of 2010
0000
00.00
0000-00-00
000000&0
0000
CyDex Pharmaceuticals Competitors (1)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
00000 000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
CyDex Pharmaceuticals Patents
CyDex Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2019532927-A | Formulation containing acetaminophen and sulfoalkyl ether cyclodextrin | Pending | 16-Sep-2016 | 00000000 | 0 |
EP-3512511-A4 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | Pending | 16-Sep-2016 | 0000000000 | 0 |
EP-3512511-A1 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | Pending | 16-Sep-2016 | 00000000 | |
US-20190255000-A1 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | Pending | 16-Sep-2016 | 0000000000 | |
CA-3036989-A1 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | Pending | 16-Sep-2016 | A61K31/167 |
CyDex Pharmaceuticals Signals
CyDex Pharmaceuticals Former Investors (9)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Clariden Investment | Venture Capital | Minority | 000 0000 | 000000 0 | |
Eastman Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Edelman Financial Services | Asset Manager | Minority | 000 0000 | 000000 0 | |
Private Equity Direct Finance | PE/Buyout | Minority | 000 0000 | 000000 0 | |
RiverVest Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 |